Abilify Asimtufii (Aripiprazole) Patent Expiration, LOE Window & CMS Spending
Abilify Asimtufii (Aripiprazole) by Otsuka Pharmaceutical: FDA Orange Book LOE 2033-04-23, 18 AB generics, $175.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Otsuka Pharmaceutical |
| FDA Application & Pathway | N217006 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2033-04-23 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 18 |
| 2024 CMS Total Public Spend | $175.6M |
| 2024 Medicare Part D Spend | $63.1M |
| 2024 Medicaid Spend | $112.5M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 3.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.